



## **Orchard Therapeutics to Present at the Cowen 39th Annual Health Care Conference on March 11, 2019**

March 4, 2019

BOSTON and LONDON, March 04, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced that the company will present at the Cowen 39<sup>th</sup> Annual Health Care Conference in Boston on Monday, March 11, 2019 at 2:10 p.m. ET.

A live webcast of the presentation will be available under "News & Events" in the Investors & Media section of the company's website at [orchard-tx.com](http://orchard-tx.com). A replay of the webcast will be archived on the Orchard website following the presentation.

### **About Orchard**

Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies.

Orchard's portfolio of autologous, *ex vivo*, hematopoietic stem cell gene therapies includes Strimvelis, the first such treatment approved by the European Medicines Agency for severe combined immune deficiency due to adenosine deaminase deficiency (ADA-SCID). Additional programs for neurometabolic disorders, primary immune deficiencies and hemoglobinopathies include three advanced registrational studies for metachromatic leukodystrophy (MLD), ADA-SCID and Wiskott-Aldrich syndrome (WAS), clinical programs for X-linked chronic granulomatous disease (X-CGD) and transfusion-dependent beta-thalassemia (TDBT), as well as an extensive preclinical pipeline.

Orchard currently has offices in the U.K. and the U.S., including London, San Francisco and Boston.

### **Contacts**

#### **Corporate & Investor contact**

Renee Leck  
Director, Investor Relations  
Orchard Therapeutics  
+1 862-242-0764  
[Renee.Leck@orchard-tx.com](mailto:Renee.Leck@orchard-tx.com)

#### **Media contact**

Allison Blum, Ph.D.  
LifeSci Public Relations  
+1 516-655-0842  
[Allison@lifescipublicrelations.com](mailto:Allison@lifescipublicrelations.com)

Source: Orchard Therapeutics Limited